Spring Health vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 59)
Spring Health logo

Spring Health

ChallengerHealthcare Tech

Mental Health Benefits & AI Care Matching

AI mental health benefits platform. $3.3B valuation. 50M+ lives. Raised $460M+. Acquiring Alma (Jan 2026). Founded 2016, NYC. Potential IPO candidate 2026. Private.

AI VisibilityBeta
Overall Score
C59
Category Rank
#135 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
56
Perplexity
59
Gemini
54

About

Spring Health is a global mental health technology company founded in 2016 by CEO April Koh and President Adam Chekroud, headquartered in New York City. Raised over $460M including a $100M Series E (July 2024) led by Generation Investment Management at $3.3B valuation. April Koh became the youngest woman to lead a multibillion-dollar startup at 29.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

59
Overall Score
80
#135
Category Rank
#18
77
AI Consensus
83
stable
Trend
stable
56
ChatGPT
78
59
Perplexity
78
54
Gemini
80
62
Claude
84
63
Grok
77

Key Details

Category
Mental Health Benefits & AI Care Matching
Enterprise
Tier
Challenger
Leader
Entity Type
platform
company

Capabilities & Ecosystem

Capabilities

Only Spring Health
Mental Health Benefits & AI Care Matching

Integrations

Only Spring Health
Only Bristol Myers Squibb
Spring Health is classified as platform. Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.